Unlocking the Potential of B3GALT6: A Galactosyltransferase Enzyme as a Drug Target and Biomarker

Target Name: B3GALT6

NCBI ID: G126792

B3GALT6

Unlocking the Potential of B3GALT6: A Galactosyltransferase Enzyme as a Drug Target and Biomarker

Galactosyltransferase enzymes are involved in the transfer of Galactose residues from cell surface proteins to the cytoplasmic proteins, thereby modifying their properties and determining their functions. B3GALT6, a member of the B3GALT gene family, is an enzyme involved in the transfer of Galactose residues from the cell surface to various cytoplasmic proteins. In this article, we will explore the potential of B3GALT6 as a drug target and biomarker.

B3GALT6 Structure and Function

B3GALT6 is a 23-kDa protein that consists of 156 amino acid residues. The protein has a unique structure, with a catalytic active site, a 尾-sheet, and a C-terminal hypervariable region (HVR) that is involved in its catalytic activity. B3GALT6 functions as a Galactosyltransferase, catalyzing the transfer of Galactose residues from cell surface proteins to various cytoplasmic proteins. The substrate proteins for B3GALT6 include, but are not limited to, cytoskeletal proteins, actinin proteins, and neurotransmitter receptors.

B3GALT6 is expressed in various tissues and cells, including muscle, heart, brain, and cancer cells. It is also involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. In addition, B3GALT6 has been shown to play a role in the development and progression of various diseases, including cancer.

Drug Target Potential

The potential of B3GALT6 as a drug target is high due to its unique structure and the various functions it is involved in. One of the main targets for B3GALT6 is the regulation of cellular processes, such as cell adhesion and migration. B3GALT6 has been shown to play a role in the regulation of cell-cell adhesion by interacting with cadherins, a protein that is involved in cell-cell adhesion. In addition, B3GALT6 has been shown to regulate the migration of cancer cells by interacting with vimentin, a protein that is involved in cell migration.

Another potential target for B3GALT6 is the regulation of neurotransmitter release and signaling. B3GALT6 has been shown to play a role in the regulation of neurotransmitter release by interacting with postsynaptic density protein (PDP), a protein that is involved in neurotransmitter release. In addition, B3GALT6 has been shown to play a role in the regulation of neurotransmitter signaling by interacting with neurotransmitter receptors.

Biomarker Potential

B3GALT6 has the potential to serve as a biomarker for various diseases, including cancer. The regulation of B3GALT6 by various diseases, including cancer, can be detected by using techniques such as Western blotting, immunofluorescence, and In vitro assays. For example, B3GALT6 has been shown to be overexpressed in various cancer tissues, including breast cancer, lung cancer, and colon cancer.

In addition, B3GALT6 has been shown to play a role in the regulation of cellular processes, including cell adhesion and migration, which can be used as biomarkers for diseases that affect these processes, such as cancer. For example, B3GALT6 has

Protein Name: Beta-1,3-galactosyltransferase 6

Functions: Beta-1,3-galactosyltransferase that transfers galactose from UDP-galactose to substrates with a terminal beta-linked galactose residue. Has a preference for galactose-beta-1,4-xylose that is found in the linker region of glycosaminoglycans, such as heparan sulfate and chondroitin sulfate. Has no activity towards substrates with terminal glucosamine or galactosamine residues

The "B3GALT6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B3GALT6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets